HOME >> BIOLOGY >> NEWS
Results of pivotal study for GlaxoSmithKline's Valtrex published in New England Journal of Medicine

Research Triangle Park, N.C., January 1, 2004 GlaxoSmithKline today announced the publication of results from a clinical trial evaluating VALTREX (valacyclovir HCl), an oral antiviral, in the reduction of transmission of genital herpes, in the Jan. 1 edition of the New England Journal of Medicine1. VALTREX significantly reduced the risk of transmitting herpes infection to a heterosexual partner as compared to placebo. Results from this trial have been used to support a new label indication for VALTREX in the reduction in risk of transmission of genital herpes when used in combination with safer sex practices. This new indication has been approved in the USA, Australia and Finland.

The transmission study with VALTREX published in the latest edition of NEJM was a randomized, double-blind, placebo-controlled trial involving 1,484 healthy, heterosexual, monogamous couples in 21 countries. The primary endpoint of the study was to evaluate the reduction in risk of transmission of symptomatic genital herpes (signs or symptoms of GH confirmed with a lab test) to an uninfected partner with use of suppressive therapy with VALTREX. The study showed that once-daily suppressive therapy with VALTREX 500 mg caplets reduced the risk of transmission of symptomatic genital herpes by 75 percent versus placebo (0.5 percent vs 2.2 percent). In addition, suppressive therapy with VALTREX reduced the risk of overall acquisition of the virus (with or without symptoms confirmed by a lab test) by 48 percent versus placebo (1.9 percent vs. 3.6 percent). In addition, VALTREX significantly reduced the number of recurrences in the infected partner versus placebo, consistent with previous studies.

Throughout the eight-month study, all couples were counselled on safer sex practices at all study visits. The principles of safer sex practices were (1) to avoid sexual contact when the infected partner had any symptoms of genital herpes and (2) consistent and correct use of condo
'"/>

Contact: Mary Faye Dark, GlaxoSmithKline
919-483-2839
Hill and Knowlton
1-Jan-2004


Page: 1 2 3

Related biology news :

1. Results from open-label Raptiva study suggest continued benefit with long-term treatment
2. NASA Materials Conference Features Science Results, Experts on Technologies for Exploration
3. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
4. Encouraging Results In Preclinical Studies Of Parkinsons Disease Gene Therapy
5. Quicker Implementation Of Research Results
6. Results Of Poisoning Visible In Urine
7. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
8. New Gene Therapy Technique Results In Efficient Gene Delivery
9. False Security: You Cant Always Believe The Results Of A Genetic Test
10. Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps
11. Results Of Hog-Stress Study May Lead To Better Management Methods

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/12/2018)... Calif. (PRWEB) , ... September 10, 2018 , ... ... a paper detailing the performance of its new Multiplexed Ion Beam Imaging (MIBITM) ... September 6 issue. This study will also be shared during a webinar presented ...
(Date:9/7/2018)... ... September 05, 2018 , ... ... mAb manufacturing facility late last year, IPS-Integrated Project Services, LLC and G-CON Manufacturing ... autologous cell therapies. The iCON solution provides a pre-fabricated modular cleanroom infrastructure for ...
(Date:8/31/2018)... , ... August 30, 2018 , ... ... offering a complimentary cryogenic freezer program for new clients. The freezers are very ... regenerative biologics from R3 Stem Cell consist of amniotic and umbilical cord tissue. ...
Breaking Biology News(10 mins):
(Date:8/31/2018)... ... August 30, 2018 , ... Small, wireless and networked describes more than the ... connected, too. Draper’s latest system is tiny in size, but is poised to make ... in the new implant design is the growing awareness that disease often involves complex ...
(Date:8/29/2018)... Calif. (PRWEB) , ... August 28, 2018 , ... ... scientists from around the world, is proud to announce the launch of a new ... offers for a chance to win one of LabRoots most popular shirts. , Throughout ...
(Date:8/23/2018)... ... August 23, 2018 , ... Visikol began ... Dr. Thomas Villani. Through support from advisors, mentors, the Rutgers Technology Transfer team and ... Visikol’s path from an idea to a successful biotech company has been a circuitous ...
(Date:8/17/2018)... (PRWEB) , ... August 16, 2018 , ... ... testing, announced their results from the AmbryShare project were published today in JAMA ... in the largest exome study ever conducted. , Every year hereditary breast cancer ...
Breaking Biology Technology:
Cached News: